Ligand ID: LEV

Drugbank ID:
Lenvatinib
(DB09078)

Indication:
Lenvatinib is a receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma.


LIST OF BINDING INTERFACES for query 'DB09078'
(Click on the 'Details' column to view details on interfaces and similar patterns of amino acids)
Click on the 'View' column to view patterns on the structural viewer)
DrReposER ID PDB Ligand Drug Organism Macromolecule Pfam Res. Interface HETATM View Details
3WZD_A_LEVA12013wzd LEVLenvatinib
(DB09078) 		Homo sapiens VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 PK_Tyr_Ser-Thr 20LEU A 840
GLY A 841
VAL A 848
ALA A 866
LYS A 868
GLU A 885
ILE A 888
LEU A 889
VAL A 899
VAL A 916
GLU A 917
PHE A 918
CYS A 919
LYS A 920
GLY A 922
LEU A1035
CYS A1045
ASP A1046
PHE A1047
LEU A1049
LEV A1201
5ZV2_A_LEVA8015zv2 LEVLenvatinib
(DB09078) 		Homo sapiens FIBROBLAST GROWTH FACTOR RECEPTOR 1 PK_Tyr_Ser-Thr 21LEU A 484
GLY A 485
PHE A 489
VAL A 492
ALA A 512
LYS A 514
GLU A 531
MET A 535
ILE A 545
VAL A 561
GLU A 562
TYR A 563
ALA A 564
SER A 565
GLY A 567
GLU A 571
LEU A 630
ALA A 640
ASP A 641
PHE A 642
LEU A 644
LEV A 801
DrReposER ID PDB Ligand Drug Organism Macromolecule Pfam Res. Interface HETATM View Details